Phase II, Multicenter, Randomized Trial of CPX-351 (cytarabine:daunorubicin) Liposome Injection versus Intensive Salvage Therapy in Adults with First Relapse AML

BACKGROUND: CPX-351 is a liposome-encapsulated fixed-molar ratio formulation of cytarabine and daunorubicin that exploits molar ratio-dependent drug-drug synergy to enhance anti-leukemic efficacy. METHODS: This Phase II study randomized 125 patients 2:1 to CPX-351 or investigator’s choice of first s...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer
Main Authors: Cortes, Jorge E., Goldberg, Stuart L., Feldman, Eric J., Rizzeri, David A., Hogge, Donna E., Larson, Melissa, Pigneux, Arnaud, Recher, Christian, Schiller, Gary, Warzocha, Krzysztof, Kantarjian, Hagop, Louie, Arthur C., Kolitz, Jonathan E.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5542857/
https://ncbi.nlm.nih.gov/pubmed/25223583
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.28974
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados